Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

被引：3
|
作者：
Ilyas, Rimal [1 ]
Johnson, Isla McKerrow [1 ]
McCullough, Kristen [2 ]
Al-Kali, Aref [3 ]
Alkhateeb, Hassan B. [3 ]
Begna, Kebede [3 ]
Mangaonkar, Abhishek A. [3 ]
Litzow, Mark R. [3 ]
Hogan, William J. [3 ]
Shah, Mithun, V [3 ]
Patnaik, Mrinal M. M. [3 ]
Pardanani, Animesh [3 ]
Tefferi, Ayalew [3 ]
Gangat, Naseema [3 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Div Pharmacol, Rochester, MN USA
[3] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165491
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1286 / 1287
页数：2
相关论文
共 50 条
  • [31] Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study
    Geramita, Emily
    Wang, Hong
    Bastacky, Melissa
    Cohen, Jessica
    Shallis, Rory Michael
    Badar, Talha
    Litzow, Mark R.
    Im, Annie
    BLOOD, 2022, 140 : 6187 - 6188
  • [32] Venetoclax plus obinutuzumab therapy for front-line treatment of chronic lymphocytic leukaemia
    Seymour, John F.
    LANCET ONCOLOGY, 2020, 21 (09): : 1128 - 1130
  • [33] Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy
    Cojbasic, Irena
    Macukanovic-Golubovic, Lana
    Vucic, Miodrag
    Tijanic, Ivan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : 696 - 702
  • [34] Response to Olutasidenib in Patients With Acute Myeloid Leukemia (AmL) Following Venetoclax Failure
    Cortes, Jorge
    Jonas, Brian A.
    Di Trapani, Francois
    Sheppard, Aaron
    Watts, Justin M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S318 - S318
  • [35] Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent
    On, Sandy
    Rath, Carolyn G.
    Lan, Michelle
    Wu, Bobby
    Lau, Kimberly M.
    Cheung, Edna
    Alegria, William
    Young, Rebecca
    Tan, Marisela
    Kim, Carrie
    Phun, Jennifer
    Patel, Nimish
    Mannis, Gabriel
    Logan, Aaron C.
    Kennedy, Vanessa
    Goodman, Aaron
    Taplitz, Randy A.
    Young, Patricia A.
    Wen, Raymond
    Saunders, Ila M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 (01) : 63 - 70
  • [36] Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax plus Hypomethylating Agent
    Elbeih, Azeem
    Ghosoun, Nour
    Mccullough, Kristen B.
    Johnson, Isla
    Abdelmagid, Maymona
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede
    Elliott, Michelle A.
    Mangaonkar, Abhishek A.
    Matin, Aasiya
    Saliba, Antoine N.
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Mangaonkar, Abhisek
    Shah, Aasiya Mithun, V
    Patnaik, Mrinal M.
    Pardanani, Animesh D.
    Badar, Talha
    Murthy, Hemant S.
    Foran, James M.
    Palmer, Jeanne
    Sproat, Lisa
    Khera, Nandita
    Arana, Cecilia Y.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2024, 144 : 2853 - 2853
  • [37] Validation of the Charlson Comorbidity Index Model in Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax
    Bouligny, Ian
    Murray, Graeme
    Thuy Ho
    Gor, Juhi
    Zacholski, Kyle
    Wages, Nolan
    Grant, Steven
    Maher, Keri
    BLOOD, 2023, 142
  • [38] Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent plus Venetoclax Vs. High Intensity Regimens
    Li Krackeler, Margaret
    Moskoff, Benjamin
    Othman, Tamer
    Azenkot, Tali
    Beechinor, Ryan J.
    Rosenberg, Aaron S.
    Esteghamat, Naseem S.
    Hoeg, Rasmus T.
    Tuscano, Joseph M.
    Jonas, Brian A.
    BLOOD, 2022, 140 : 8926 - 8928
  • [39] ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival
    McCullough, Kristen
    Karrar, Omer
    Iftikhar, Moazah
    Abdelmagid, Maymona
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Saliba, Antoine
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Patnaik, Mrinal M.
    Pardanani, Animesh D.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2023, 142
  • [40] Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam M.
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Benton, Christopher B.
    Benton, Christopher B.
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa E.
    Jain, Nitin
    Kornblau, Steven M.
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias
    Masarova, Lucia
    Rytting, Michael E.
    Thompson, Philip A.
    Wang, Sa A.
    Konoplev, Sergej
    Chen, Zhining
    Goswami, Maitrayee
    Maduike, Rita
    Guerrero, Julio A.
    Zhang, Qi
    Cavazos, Antonio
    Ma, Helen
    Bivins, Carol A.
    Wade, Allison
    Adewale, Shadiat L.
    Tse, Susan
    Thomas, Robin
    Vaughan, Kenneth
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD, 2019, 134
12345